|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 11/13/2025
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Gene Editing for Head and Neck Cancer Treatment
Application
Method for delivering gene-editing therapeutic in head and neck cancers.
Key Benefits
CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene.
Liquid nanoparticle encapsulation permitting in vivo delivery.
Market Summary
Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025
Contributor(s): Yong Teng, Yamin Li
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 11/3/2025
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Molecules Targeting Inflammatory Signaling
Application
A group of small molecules for treating central and peripheral diseases associated with inflammation.
Key Benefits
Applicable to a wide variety of central nervous system and peripheral diseases.
Can bypass side effects of existing therapeutics targeting similar inflammatory pathways.
High target selectivity and aqueous solubility.
Capability...
Published: 11/13/2025
Contributor(s): Raymond (Ray) Dingledine, Radhika Amaradhi, Shabber Mohammed, Thota Ganesh
|
|
MKK3/MYC Protein-Protein Interaction Inhibitor Overcomes Resistant Non-Small Cell Lung Cancer
Application
A therapeutic use for SGI-1027 in the treatment of Osimertinib-resistant non-small cell lung cancer (NSCLC).
Key Benefits
The MKK3/MYC protein-protein interaction inhibitor SGI-1027 effectively decreases MYC levels in Osimertinib-resistant NSCLC cell lines.
The combination of SGI-1027 with Osimertinib offers synergistic benefits over...
Published: 10/15/2025
Contributor(s): Andrey Ivanov, Haian Fu, Shi-Yong Sun, Zhen Chen
|
|
Assessment of Tumor Response to Treatment Using Level Set Clustering in PET Images
Application
Tumor response algorithm that corrects for anatomical changes and robustly identifies local changes in serial PET images through a clustering algorithm.
Key Benefits
Robust to noise and outliers and can tolerate imperfections in data acquisition.
Could be applicable to many other imaging modalities in radiation therapy.
More accurately...
Published: 11/7/2025
Contributor(s): Timothy Fox, Eduard Schreibmann
|
|
Enhanced Delivery and Efficacy of Antisense Drugs via Covalently Linked Nanodisc Scaffolds
Application
A synthetic nanodisc (ND) scaffold for delivering antisense oligonucleotides (ASOs) for the treatment of disease.
Key Benefits
Improved cellular uptake and protein suppression using antisense oligos.
Longer ASO half-life compared to other ASO delivery methods.
Potential to overcome the delivery and efficacy challenges using ASOs for...
Published: 9/22/2025
Contributor(s): Khalid Salaita, Radhika Sharma
|
|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 2/13/2025
Contributor(s): Byron Au-Yeung
|
|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 7/22/2025
Contributor(s): Jack Arbiser
|
|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 11/12/2025
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
